[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fgsS0DL-VO_oCvSswzyEYBUrRbMLdhbiaTViwxCVuVpU":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":8,"truncated":9,"activeTrials":10,"phase3Count":11,"totalEnrollment":12,"activePrograms":13,"nonDrugCount":14,"topConditions":15,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"R-Pharm",[4,6,7],"R-Pharm Overseas, Inc.","R-Pharm International, LLC",75,false,10,25,18262,24,0,[16,19,21,24,26,29,32,34],{"name":17,"count":18},"Metastatic Breast Cancer",8,{"name":20,"count":18},"COVID-19",{"name":22,"count":23},"Breast Cancer",5,{"name":25,"count":23},"Rheumatoid Arthritis",{"name":27,"count":28},"Healthy",4,{"name":30,"count":31},"Cancer",3,{"name":33,"count":31},"Advanced Solid Tumors",{"name":35,"count":31},"Head and Neck Squamous Cell Carcinoma",[37,42,47,52,56,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT05092776","Efficacy and Safety of RPH-104 for Resolution and Prevention of Recurring Attacks in Adult Subjects With Familial Mediterranean Fever With Resistance to or Intolerance of Colchicine","2025-01","RPH-104",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT07435324","A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma","2025-09-29","RPH-002",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT07386938","A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer","2025-10-23","RPH-051",{"nctId":53,"briefTitle":54,"date":55,"intervention":41},"NCT05673902","Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis","2026-01",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT07597668","A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations","2026-01-12","RPH-035",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07553988","A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer","2026-05-14","RS-113, 160 mg",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07543744","A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI","2026-05-15","RPH-030",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT07517575","Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis","2026-09","OKZ q4w",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06440746","Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases","2027-04-09","Subcutaneous",{"nctId":82,"briefTitle":83,"date":84,"intervention":41},"NCT05190991","Safety and Efficacy of RPH-104 Used to Prevent Recurrent Fever Attacks in Adult Patients With Colchicine Resistant or Colchicine Intolerant Familial Mediterranean Fever","2028-12",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,179,236,269,291,313,335,353,371,394,412,434,461,479,497,515,533,551,574,592,617,635,653,671,689,879,924,999,1033,1082,1104,1131,1168,1190,1216,1243,1261,1287,1305,1331,1349,1367,1385,1403,1430,1448,1475,1493,1511,1538,1556,1574,1592,1610,1639,1657,1675,1693,1736,1762,1788,1806,1824,1849,1867,1885,1913,1931,1949,1976,1994,2012,2030,2053,2079,2097,2115,2133,2151,2179,2197,2215,2233,2263,2281,2299,2317,2335,2353,2371,2389,2407,2432,2450,2474,2492,2510,2537,2555,2573,2591,2609,2627,2685,2707],{"intervention":41,"totalTrials":94,"cells":95},7,{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":110,"PHASE3":131,"PHASE4":175,"NA":177},{"trials":97,"activeCount":14},[],{"trials":99,"activeCount":14},[100],{"nctId":101,"briefTitle":102,"status":103,"phases":104,"primaryCompletion":105,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT02667639","Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects","COMPLETED",[87],"2017-06","2016-01",35,[27],[41],{"trials":111,"activeCount":130,"soonestReadout":40},[112,122],{"nctId":38,"briefTitle":39,"status":113,"phases":114,"primaryCompletion":40,"completion":115,"start":116,"enrollment":117,"conditions":118,"interventions":121},"ACTIVE_NOT_RECRUITING",[88],"2025-10-30","2021-04-29",84,[119,120],"Familial Mediterranean Fever","FMF",[41],{"nctId":82,"briefTitle":83,"status":123,"phases":124,"primaryCompletion":84,"completion":125,"start":126,"enrollment":127,"conditions":128,"interventions":129},"RECRUITING",[88],"2029-01","2021-10-05",60,[119,120],[41],2,{"trials":132,"activeCount":174,"soonestReadout":55},[133,145,156,167],{"nctId":134,"briefTitle":135,"status":136,"phases":137,"primaryCompletion":138,"completion":139,"start":140,"enrollment":141,"conditions":142,"interventions":144},"NCT05107934","Efficacy and Safety of RPH-104 Treatment in Patients With Recurrent Pericarditis","SUSPENDED",[88,89],"2027-05","2027-10","2025-12",80,[143],"Recurrent Pericarditis",[41],{"nctId":146,"briefTitle":147,"status":103,"phases":148,"primaryCompletion":149,"completion":150,"start":151,"enrollment":152,"conditions":153,"interventions":155},"NCT04692766","Study to Evaluate the Efficacy and Safety of RPH-104 Treatment in Patients With Idiopathic Recurrent Pericarditis",[88,89],"2022-01-24","2022-03-22","2020-02-12",20,[154],"Pericarditis",[41],{"nctId":157,"briefTitle":158,"status":159,"phases":160,"primaryCompletion":161,"completion":161,"start":162,"enrollment":14,"conditions":163,"interventions":166},"NCT05432960","Efficacy and Safety Clinical Study of RPH-104 in Adult Onset Still's Disease (AOSD)","WITHDRAWN",[89],"2025-08","2023-12",[164,165],"Adult-Onset Still's Disease","AOSD",[41],{"nctId":53,"briefTitle":54,"status":113,"phases":168,"primaryCompletion":55,"completion":55,"start":169,"enrollment":170,"conditions":171,"interventions":173},[89],"2020-12-11",17,[172],"Idiopathic Recurrent Pericarditis",[41],1,{"trials":176,"activeCount":14},[],{"trials":178,"activeCount":14},[],{"intervention":180,"totalTrials":28,"cells":181},"docetaxel",{"EARLY_PHASE1":182,"PHASE1":184,"PHASE2":197,"PHASE3":211,"PHASE4":232,"NA":234},{"trials":183,"activeCount":14},[],{"trials":185,"activeCount":14},[186],{"nctId":187,"briefTitle":188,"status":103,"phases":189,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":193,"interventions":194},"NCT07435311","A Phase I Comparative Study of Pharmacokinetics, Safety, and Efficacy of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma",[87],"2024-07-17","2020-06-15",118,[35],[46,195,196,180],"Erbitux®","cisplatin",{"trials":198,"activeCount":14},[199],{"nctId":200,"briefTitle":201,"status":103,"phases":202,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":207,"interventions":208},"NCT00490646","A Phase II Combination of Trastuzumab and Ixabepilone Versus Trastuzumab and Docetaxel in Patients With Advanced and\u002For Metastatic Breast Cancer",[88],"2011-06","2011-11","2008-02",50,[17],[209,180,210],"ixabepilone","trastuzumab",{"trials":212,"activeCount":130,"soonestReadout":45},[213,224],{"nctId":48,"briefTitle":49,"status":113,"phases":214,"primaryCompletion":50,"completion":215,"start":216,"enrollment":217,"conditions":218,"interventions":220},[89],"2027-05-24","2024-08-09",246,[219,17],"Locally Advanced Breast Cancer",[51,221,222,223],"Docetaxel","Perjeta®","Trastuzumab",{"nctId":43,"briefTitle":44,"status":113,"phases":225,"primaryCompletion":45,"completion":226,"start":227,"enrollment":228,"conditions":229,"interventions":230},[89],"2026-06-21","2024-08-08",161,[35],[46,195,231,221],"Cisplatin",{"trials":233,"activeCount":14},[],{"trials":235,"activeCount":14},[],{"intervention":231,"totalTrials":31,"cells":237},{"EARLY_PHASE1":238,"PHASE1":240,"PHASE2":257,"PHASE3":259,"PHASE4":265,"NA":267},{"trials":239,"activeCount":14},[],{"trials":241,"activeCount":14},[242,253],{"nctId":243,"briefTitle":244,"status":103,"phases":245,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":249,"interventions":251},"NCT00832117","Phase I Combination Ixabepilone + Cisplatin",[87],"2011-01","2009-05",30,[250],"Non Small Cell Lung Cancer",[252,231,252,231],"Ixabepilone",{"nctId":187,"briefTitle":188,"status":103,"phases":254,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":255,"interventions":256},[87],[35],[46,195,196,180],{"trials":258,"activeCount":14},[],{"trials":260,"activeCount":174,"soonestReadout":45},[261],{"nctId":43,"briefTitle":44,"status":113,"phases":262,"primaryCompletion":45,"completion":226,"start":227,"enrollment":228,"conditions":263,"interventions":264},[89],[35],[46,195,231,221],{"trials":266,"activeCount":14},[],{"trials":268,"activeCount":14},[],{"intervention":210,"totalTrials":130,"cells":270},{"EARLY_PHASE1":271,"PHASE1":273,"PHASE2":275,"PHASE3":281,"PHASE4":287,"NA":289},{"trials":272,"activeCount":14},[],{"trials":274,"activeCount":14},[],{"trials":276,"activeCount":14},[277],{"nctId":200,"briefTitle":201,"status":103,"phases":278,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":279,"interventions":280},[88],[17],[209,180,210],{"trials":282,"activeCount":174,"soonestReadout":50},[283],{"nctId":48,"briefTitle":49,"status":113,"phases":284,"primaryCompletion":50,"completion":215,"start":216,"enrollment":217,"conditions":285,"interventions":286},[89],[219,17],[51,221,222,223],{"trials":288,"activeCount":14},[],{"trials":290,"activeCount":14},[],{"intervention":46,"totalTrials":130,"cells":292},{"EARLY_PHASE1":293,"PHASE1":295,"PHASE2":301,"PHASE3":303,"PHASE4":309,"NA":311},{"trials":294,"activeCount":14},[],{"trials":296,"activeCount":14},[297],{"nctId":187,"briefTitle":188,"status":103,"phases":298,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":299,"interventions":300},[87],[35],[46,195,196,180],{"trials":302,"activeCount":14},[],{"trials":304,"activeCount":174,"soonestReadout":45},[305],{"nctId":43,"briefTitle":44,"status":113,"phases":306,"primaryCompletion":45,"completion":226,"start":227,"enrollment":228,"conditions":307,"interventions":308},[89],[35],[46,195,231,221],{"trials":310,"activeCount":14},[],{"trials":312,"activeCount":14},[],{"intervention":195,"totalTrials":130,"cells":314},{"EARLY_PHASE1":315,"PHASE1":317,"PHASE2":323,"PHASE3":325,"PHASE4":331,"NA":333},{"trials":316,"activeCount":14},[],{"trials":318,"activeCount":14},[319],{"nctId":187,"briefTitle":188,"status":103,"phases":320,"primaryCompletion":190,"completion":190,"start":191,"enrollment":192,"conditions":321,"interventions":322},[87],[35],[46,195,196,180],{"trials":324,"activeCount":14},[],{"trials":326,"activeCount":174,"soonestReadout":45},[327],{"nctId":43,"briefTitle":44,"status":113,"phases":328,"primaryCompletion":45,"completion":226,"start":227,"enrollment":228,"conditions":329,"interventions":330},[89],[35],[46,195,231,221],{"trials":332,"activeCount":14},[],{"trials":334,"activeCount":14},[],{"intervention":51,"totalTrials":174,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":349,"NA":351},{"trials":338,"activeCount":14},[],{"trials":340,"activeCount":14},[],{"trials":342,"activeCount":14},[],{"trials":344,"activeCount":174,"soonestReadout":50},[345],{"nctId":48,"briefTitle":49,"status":113,"phases":346,"primaryCompletion":50,"completion":215,"start":216,"enrollment":217,"conditions":347,"interventions":348},[89],[219,17],[51,221,222,223],{"trials":350,"activeCount":14},[],{"trials":352,"activeCount":14},[],{"intervention":222,"totalTrials":174,"cells":354},{"EARLY_PHASE1":355,"PHASE1":357,"PHASE2":359,"PHASE3":361,"PHASE4":367,"NA":369},{"trials":356,"activeCount":14},[],{"trials":358,"activeCount":14},[],{"trials":360,"activeCount":14},[],{"trials":362,"activeCount":174,"soonestReadout":50},[363],{"nctId":48,"briefTitle":49,"status":113,"phases":364,"primaryCompletion":50,"completion":215,"start":216,"enrollment":217,"conditions":365,"interventions":366},[89],[219,17],[51,221,222,223],{"trials":368,"activeCount":14},[],{"trials":370,"activeCount":14},[],{"intervention":80,"totalTrials":174,"cells":372},{"EARLY_PHASE1":373,"PHASE1":375,"PHASE2":377,"PHASE3":379,"PHASE4":390,"NA":392},{"trials":374,"activeCount":14},[],{"trials":376,"activeCount":14},[],{"trials":378,"activeCount":14},[],{"trials":380,"activeCount":174,"soonestReadout":79},[381],{"nctId":77,"briefTitle":78,"status":123,"phases":382,"primaryCompletion":79,"completion":383,"start":384,"enrollment":385,"conditions":386,"interventions":388},[88,89],"2028-12-25","2023-08-23",138,[387],"Lung Diseases, Interstitial",[80,389],"SC injections of Placebo every 4 weeks (q4w), one injection of 0.4 mL",{"trials":391,"activeCount":14},[],{"trials":393,"activeCount":14},[],{"intervention":389,"totalTrials":174,"cells":395},{"EARLY_PHASE1":396,"PHASE1":398,"PHASE2":400,"PHASE3":402,"PHASE4":408,"NA":410},{"trials":397,"activeCount":14},[],{"trials":399,"activeCount":14},[],{"trials":401,"activeCount":14},[],{"trials":403,"activeCount":174,"soonestReadout":79},[404],{"nctId":77,"briefTitle":78,"status":123,"phases":405,"primaryCompletion":79,"completion":383,"start":384,"enrollment":385,"conditions":406,"interventions":407},[88,89],[387],[80,389],{"trials":409,"activeCount":14},[],{"trials":411,"activeCount":14},[],{"intervention":75,"totalTrials":174,"cells":413},{"EARLY_PHASE1":414,"PHASE1":416,"PHASE2":418,"PHASE3":428,"PHASE4":430,"NA":432},{"trials":415,"activeCount":14},[],{"trials":417,"activeCount":14},[],{"trials":419,"activeCount":174,"soonestReadout":74},[420],{"nctId":72,"briefTitle":73,"status":123,"phases":421,"primaryCompletion":74,"completion":422,"start":423,"enrollment":424,"conditions":425,"interventions":427},[88],"2030-06","2023-03-17",71,[426],"Juvenile Idiopathic Arthritis",[75,75],{"trials":429,"activeCount":14},[],{"trials":431,"activeCount":14},[],{"trials":433,"activeCount":14},[],{"intervention":65,"totalTrials":174,"cells":435},{"EARLY_PHASE1":436,"PHASE1":438,"PHASE2":440,"PHASE3":455,"PHASE4":457,"NA":459},{"trials":437,"activeCount":14},[],{"trials":439,"activeCount":14},[],{"trials":441,"activeCount":174,"soonestReadout":64},[442],{"nctId":62,"briefTitle":63,"status":113,"phases":443,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":449},[88],"2027-05-09","2024-10-24",120,[448],"Metastatic Castration-resistant Prostate Cancer",[65,450,451,452,453,454],"RS-113, 240 mg","RS-113, 320 mg","Abiraterone","Prednisolone","Androgen deprivation therapy",{"trials":456,"activeCount":14},[],{"trials":458,"activeCount":14},[],{"trials":460,"activeCount":14},[],{"intervention":450,"totalTrials":174,"cells":462},{"EARLY_PHASE1":463,"PHASE1":465,"PHASE2":467,"PHASE3":473,"PHASE4":475,"NA":477},{"trials":464,"activeCount":14},[],{"trials":466,"activeCount":14},[],{"trials":468,"activeCount":174,"soonestReadout":64},[469],{"nctId":62,"briefTitle":63,"status":113,"phases":470,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":471,"interventions":472},[88],[448],[65,450,451,452,453,454],{"trials":474,"activeCount":14},[],{"trials":476,"activeCount":14},[],{"trials":478,"activeCount":14},[],{"intervention":451,"totalTrials":174,"cells":480},{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":482,"activeCount":14},[],{"trials":484,"activeCount":14},[],{"trials":486,"activeCount":174,"soonestReadout":64},[487],{"nctId":62,"briefTitle":63,"status":113,"phases":488,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":489,"interventions":490},[88],[448],[65,450,451,452,453,454],{"trials":492,"activeCount":14},[],{"trials":494,"activeCount":14},[],{"trials":496,"activeCount":14},[],{"intervention":452,"totalTrials":174,"cells":498},{"EARLY_PHASE1":499,"PHASE1":501,"PHASE2":503,"PHASE3":509,"PHASE4":511,"NA":513},{"trials":500,"activeCount":14},[],{"trials":502,"activeCount":14},[],{"trials":504,"activeCount":174,"soonestReadout":64},[505],{"nctId":62,"briefTitle":63,"status":113,"phases":506,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":507,"interventions":508},[88],[448],[65,450,451,452,453,454],{"trials":510,"activeCount":14},[],{"trials":512,"activeCount":14},[],{"trials":514,"activeCount":14},[],{"intervention":453,"totalTrials":174,"cells":516},{"EARLY_PHASE1":517,"PHASE1":519,"PHASE2":521,"PHASE3":527,"PHASE4":529,"NA":531},{"trials":518,"activeCount":14},[],{"trials":520,"activeCount":14},[],{"trials":522,"activeCount":174,"soonestReadout":64},[523],{"nctId":62,"briefTitle":63,"status":113,"phases":524,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":525,"interventions":526},[88],[448],[65,450,451,452,453,454],{"trials":528,"activeCount":14},[],{"trials":530,"activeCount":14},[],{"trials":532,"activeCount":14},[],{"intervention":454,"totalTrials":174,"cells":534},{"EARLY_PHASE1":535,"PHASE1":537,"PHASE2":539,"PHASE3":545,"PHASE4":547,"NA":549},{"trials":536,"activeCount":14},[],{"trials":538,"activeCount":14},[],{"trials":540,"activeCount":174,"soonestReadout":64},[541],{"nctId":62,"briefTitle":63,"status":113,"phases":542,"primaryCompletion":64,"completion":444,"start":445,"enrollment":446,"conditions":543,"interventions":544},[88],[448],[65,450,451,452,453,454],{"trials":546,"activeCount":14},[],{"trials":548,"activeCount":14},[],{"trials":550,"activeCount":14},[],{"intervention":60,"totalTrials":174,"cells":552},{"EARLY_PHASE1":553,"PHASE1":555,"PHASE2":566,"PHASE3":568,"PHASE4":570,"NA":572},{"trials":554,"activeCount":14},[],{"trials":556,"activeCount":174,"soonestReadout":59},[557],{"nctId":57,"briefTitle":58,"status":113,"phases":558,"primaryCompletion":59,"completion":559,"start":560,"enrollment":561,"conditions":562,"interventions":564},[87],"2027-12-20","2025-04-16",180,[563],"Multiple Sclerosis",[60,565],"Ocrevus®",{"trials":567,"activeCount":14},[],{"trials":569,"activeCount":14},[],{"trials":571,"activeCount":14},[],{"trials":573,"activeCount":14},[],{"intervention":565,"totalTrials":174,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":584,"PHASE3":586,"PHASE4":588,"NA":590},{"trials":577,"activeCount":14},[],{"trials":579,"activeCount":174,"soonestReadout":59},[580],{"nctId":57,"briefTitle":58,"status":113,"phases":581,"primaryCompletion":59,"completion":559,"start":560,"enrollment":561,"conditions":582,"interventions":583},[87],[563],[60,565],{"trials":585,"activeCount":14},[],{"trials":587,"activeCount":14},[],{"trials":589,"activeCount":14},[],{"trials":591,"activeCount":14},[],{"intervention":70,"totalTrials":174,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":595,"activeCount":14},[],{"trials":597,"activeCount":174,"soonestReadout":69},[598],{"nctId":67,"briefTitle":68,"status":123,"phases":599,"primaryCompletion":69,"completion":600,"start":601,"enrollment":561,"conditions":602,"interventions":604},[87],"2028-08","2025-04-17",[603],"Metastatic Colorectal Cancer",[70,605,606,607,608],"Vectibix®","Irinotecan","Calcium Folinate","Fluorouracil",{"trials":610,"activeCount":14},[],{"trials":612,"activeCount":14},[],{"trials":614,"activeCount":14},[],{"trials":616,"activeCount":14},[],{"intervention":605,"totalTrials":174,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":620,"activeCount":14},[],{"trials":622,"activeCount":174,"soonestReadout":69},[623],{"nctId":67,"briefTitle":68,"status":123,"phases":624,"primaryCompletion":69,"completion":600,"start":601,"enrollment":561,"conditions":625,"interventions":626},[87],[603],[70,605,606,607,608],{"trials":628,"activeCount":14},[],{"trials":630,"activeCount":14},[],{"trials":632,"activeCount":14},[],{"trials":634,"activeCount":14},[],{"intervention":606,"totalTrials":174,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":638,"activeCount":14},[],{"trials":640,"activeCount":174,"soonestReadout":69},[641],{"nctId":67,"briefTitle":68,"status":123,"phases":642,"primaryCompletion":69,"completion":600,"start":601,"enrollment":561,"conditions":643,"interventions":644},[87],[603],[70,605,606,607,608],{"trials":646,"activeCount":14},[],{"trials":648,"activeCount":14},[],{"trials":650,"activeCount":14},[],{"trials":652,"activeCount":14},[],{"intervention":607,"totalTrials":174,"cells":654},{"EARLY_PHASE1":655,"PHASE1":657,"PHASE2":663,"PHASE3":665,"PHASE4":667,"NA":669},{"trials":656,"activeCount":14},[],{"trials":658,"activeCount":174,"soonestReadout":69},[659],{"nctId":67,"briefTitle":68,"status":123,"phases":660,"primaryCompletion":69,"completion":600,"start":601,"enrollment":561,"conditions":661,"interventions":662},[87],[603],[70,605,606,607,608],{"trials":664,"activeCount":14},[],{"trials":666,"activeCount":14},[],{"trials":668,"activeCount":14},[],{"trials":670,"activeCount":14},[],{"intervention":608,"totalTrials":174,"cells":672},{"EARLY_PHASE1":673,"PHASE1":675,"PHASE2":681,"PHASE3":683,"PHASE4":685,"NA":687},{"trials":674,"activeCount":14},[],{"trials":676,"activeCount":174,"soonestReadout":69},[677],{"nctId":67,"briefTitle":68,"status":123,"phases":678,"primaryCompletion":69,"completion":600,"start":601,"enrollment":561,"conditions":679,"interventions":680},[87],[603],[70,605,606,607,608],{"trials":682,"activeCount":14},[],{"trials":684,"activeCount":14},[],{"trials":686,"activeCount":14},[],{"trials":688,"activeCount":14},[],{"intervention":252,"totalTrials":152,"cells":690},{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":783,"PHASE3":860,"PHASE4":875,"NA":877},{"trials":692,"activeCount":14},[],{"trials":694,"activeCount":14},[695,705,714,724,733,737,747,755,765,775],{"nctId":696,"briefTitle":697,"status":103,"phases":698,"primaryCompletion":699,"completion":700,"start":701,"enrollment":11,"conditions":702,"interventions":704},"NCT01018966","Study of Ixabepilone (BMS-247550) in Patients With Solid Tumors",[87],"2005-03","2005-04","2004-04",[703],"Solid Tumors",[252],{"nctId":706,"briefTitle":707,"status":103,"phases":708,"primaryCompletion":709,"completion":709,"start":710,"conditions":711,"interventions":713},"NCT00004927","BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy",[87],"2002-10","1999-07",[712],"Unspecified Adult Solid Tumor, Protocol Specific",[209],{"nctId":715,"briefTitle":716,"status":103,"phases":717,"primaryCompletion":718,"completion":718,"start":719,"enrollment":11,"conditions":720,"interventions":722},"NCT00207129","Effect of Capecitabine on the Pharmacokinetics of BMS-247550 and BMS-247550 on the Pharmacokinetics of Capecitabine and Its Metabolites in Patients With Advanced Malignancies",[87],"2005-12","2004-10",[33,721],"Neoplasms",[252,723],"Capecitabine",{"nctId":725,"briefTitle":726,"status":727,"phases":728,"start":729,"conditions":730,"interventions":731},"NCT00049244","BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer","UNKNOWN",[87],"2002-09",[22],[732,209],"capecitabine",{"nctId":243,"briefTitle":244,"status":103,"phases":734,"primaryCompletion":246,"completion":246,"start":247,"enrollment":248,"conditions":735,"interventions":736},[87],[250],[252,231,252,231],{"nctId":738,"briefTitle":739,"status":103,"phases":740,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":744,"interventions":745},"NCT00322374","Phase I Combination w\u002F Epirubicin",[87],"2009-02","2006-08",42,[17],[252,746],"Epirubicin",{"nctId":748,"briefTitle":749,"status":103,"phases":750,"primaryCompletion":751,"completion":751,"start":205,"enrollment":752,"conditions":753,"interventions":754},"NCT00568022","A Phase I Study of Ixabepilone in Combination With Capecitabine in Japanese Patients With Metastatic Breast Cancer",[87],"2010-01",9,[22],[252,723],{"nctId":756,"briefTitle":757,"status":758,"phases":759,"primaryCompletion":760,"completion":760,"start":761,"enrollment":762,"conditions":763,"interventions":764},"NCT00632424","Phase 1 Trial of Oral Ixabepilone","TERMINATED",[87],"2009-06","2008-05",23,[33],[252],{"nctId":766,"briefTitle":767,"status":103,"phases":768,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT00207090","Effect of Rifampin on the Pharmacokinetics of Ixabepilone in Patients With Advanced Cancer",[87],"2008-11","2005-09",19,[33,721],[209,774],"Rifampin",{"nctId":776,"briefTitle":777,"status":103,"phases":778,"primaryCompletion":779,"completion":779,"start":770,"enrollment":107,"conditions":780,"interventions":782},"NCT00162136","Clinical Study of Ixabepilone Administered as a 24 Hour Infusion in Patients With Solid Malignancies.",[87],"2008-07",[781],"Solid Malignancies",[252],{"trials":784,"activeCount":14},[785,794,804,808,815,823,835,843,852],{"nctId":786,"briefTitle":787,"status":103,"phases":788,"primaryCompletion":789,"completion":789,"start":790,"enrollment":791,"conditions":792,"interventions":793},"NCT01019577","Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant",[88],"2007-07","2005-10",54,[17],[252],{"nctId":795,"briefTitle":796,"status":103,"phases":797,"primaryCompletion":760,"completion":760,"start":798,"enrollment":799,"conditions":800,"interventions":802},"NCT00383149","A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer",[88],"2007-01",58,[801],"Metastatic Pancreatic Cancer",[252,803],"Cetuximab",{"nctId":200,"briefTitle":201,"status":103,"phases":805,"primaryCompletion":203,"completion":204,"start":205,"enrollment":206,"conditions":806,"interventions":807},[88],[17],[209,180,210],{"nctId":809,"briefTitle":810,"status":103,"phases":811,"primaryCompletion":798,"completion":798,"start":812,"enrollment":152,"conditions":813,"interventions":814},"NCT01027208","A Rollover Study of Ixabepilone (BMS-247550) In Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline",[88],"2006-12",[17],[252],{"nctId":816,"briefTitle":817,"status":103,"phases":818,"primaryCompletion":819,"completion":819,"start":820,"enrollment":248,"conditions":821,"interventions":822},"NCT00309049","Ixabepilone Administered as an Enteric Coated Formulation.",[87,88],"2007-05","2006-04",[30],[252,252,252],{"nctId":824,"briefTitle":825,"status":103,"phases":826,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":831,"interventions":833},"NCT00633464","Randomized Phase II Study of Ixabepilone Alone and Ixabepilone Plus Cetuximab as First-Line Treatment for Female Subjects With Triple Negative Locally Advanced Non-resectable and\u002For Metastatic Breast Cancer",[88],"2010-09","2011-05","2008-06",79,[832,17],"Triple Negative Locally Advanced Non-resectable Breast Cancer",[209,834],"ixabepilone + cetuximab",{"nctId":836,"briefTitle":837,"status":103,"phases":838,"primaryCompletion":203,"completion":203,"start":839,"enrollment":799,"conditions":840,"interventions":842},"NCT00983801","Study of Ixabepilone in Asian Subjects With Unresectable or Metastatic Gastric Cancer",[88],"2009-11",[841],"Stomach Neoplasms",[252],{"nctId":844,"briefTitle":845,"status":103,"phases":846,"primaryCompletion":812,"completion":812,"start":847,"enrollment":848,"conditions":849,"interventions":851},"NCT00080262","Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)",[88],"2004-02",125,[22,850],"Metastases",[252],{"nctId":853,"briefTitle":854,"status":103,"phases":855,"primaryCompletion":856,"completion":856,"start":761,"enrollment":857,"conditions":858,"interventions":859},"NCT00593827","Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer",[88],"2010-08",176,[17],[252,252],{"trials":861,"activeCount":14},[862],{"nctId":863,"briefTitle":864,"status":758,"phases":865,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":870,"interventions":872},"NCT00883116","A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer",[89],"2012-06","2014-02","2009-08",551,[871],"Endometrial Cancer",[252,873,874],"Doxorubicin","Paclitaxel",{"trials":876,"activeCount":14},[],{"trials":878,"activeCount":14},[],{"intervention":723,"totalTrials":23,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":897,"PHASE3":899,"PHASE4":920,"NA":922},{"trials":882,"activeCount":14},[],{"trials":884,"activeCount":14},[885,889,893],{"nctId":715,"briefTitle":716,"status":103,"phases":886,"primaryCompletion":718,"completion":718,"start":719,"enrollment":11,"conditions":887,"interventions":888},[87],[33,721],[252,723],{"nctId":725,"briefTitle":726,"status":727,"phases":890,"start":729,"conditions":891,"interventions":892},[87],[22],[732,209],{"nctId":748,"briefTitle":749,"status":103,"phases":894,"primaryCompletion":751,"completion":751,"start":205,"enrollment":752,"conditions":895,"interventions":896},[87],[22],[252,723],{"trials":898,"activeCount":14},[],{"trials":900,"activeCount":14},[901,911],{"nctId":902,"briefTitle":903,"status":103,"phases":904,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":908,"interventions":909},"NCT00082433","Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",[89],"2008-03","2003-11",1221,[30,22],[910,723],"Ixabepilone + Capecitabine",{"nctId":912,"briefTitle":913,"status":103,"phases":914,"primaryCompletion":915,"completion":905,"start":916,"enrollment":917,"conditions":918,"interventions":919},"NCT00080301","Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer",[89],"2006-11","2003-09",752,[22,850],[910,723],{"trials":921,"activeCount":14},[],{"trials":923,"activeCount":14},[],{"intervention":925,"totalTrials":23,"cells":926},"Narlaprevir",{"EARLY_PHASE1":927,"PHASE1":929,"PHASE2":954,"PHASE3":980,"PHASE4":995,"NA":997},{"trials":928,"activeCount":14},[],{"trials":930,"activeCount":14},[931,944],{"nctId":932,"briefTitle":933,"status":103,"phases":934,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":939,"interventions":940},"NCT03537404","A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs",[87],"2017-06-24","2017-06-30","2017-04-24",36,[27],[925,941,942,943],"Ritonavir","Tenofovir Disoproxil Fumarate","Raltegravir",{"nctId":945,"briefTitle":946,"status":103,"phases":947,"primaryCompletion":948,"completion":948,"start":949,"enrollment":950,"conditions":951,"interventions":953},"NCT03832426","A Pharmacokinetic Study of Narlaprevir as a Single Dose or With Ritonavir Combination in Patients With Hepatic Impairment and Healthy Matched Volunteers",[87],"2014-10-24","2013-11-08",32,[952],"Hepatic Impairment",[925,941],{"trials":955,"activeCount":14},[956,968],{"nctId":957,"briefTitle":958,"status":103,"phases":959,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT04246723","Efficacy and Safety of All-Oral Combination of Narlaprevir\u002FRitonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1",[88],"2020-04-08","2020-08-12","2019-05-06",85,[965],"Chronic Hepatitis c Genotype 1",[925,941,967],"Sofosbuvir",{"nctId":969,"briefTitle":970,"status":103,"phases":971,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":976,"interventions":978},"NCT03485846","Efficacy and Safety of All-Oral Combination of Narlaprevir\u002FRitonavir and Daclatasvir in Treatment-Naїve Patients With Chronic Hepatitis C Genotype 1b",[88],"2018-08-29","2018-11-21","2017-11-27",105,[977],"Chronic Hepatitis C Genotype 1b",[925,941,979],"Daclatasvir",{"trials":981,"activeCount":14},[982],{"nctId":983,"briefTitle":984,"status":103,"phases":985,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":990,"interventions":992},"NCT03833362","Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon\u002FRibavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study)",[89],"2016-03-23","2017-02-21","2014-05-07",420,[991],"Hepatitis C",[925,941,993,994],"Pegylated interferon alfa-2a\u002F Pegylated interferon alfa-2b","Ribavirin",{"trials":996,"activeCount":14},[],{"trials":998,"activeCount":14},[],{"intervention":941,"totalTrials":23,"cells":1000},{"EARLY_PHASE1":1001,"PHASE1":1003,"PHASE2":1013,"PHASE3":1023,"PHASE4":1029,"NA":1031},{"trials":1002,"activeCount":14},[],{"trials":1004,"activeCount":14},[1005,1009],{"nctId":932,"briefTitle":933,"status":103,"phases":1006,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":1007,"interventions":1008},[87],[27],[925,941,942,943],{"nctId":945,"briefTitle":946,"status":103,"phases":1010,"primaryCompletion":948,"completion":948,"start":949,"enrollment":950,"conditions":1011,"interventions":1012},[87],[952],[925,941],{"trials":1014,"activeCount":14},[1015,1019],{"nctId":957,"briefTitle":958,"status":103,"phases":1016,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":1017,"interventions":1018},[88],[965],[925,941,967],{"nctId":969,"briefTitle":970,"status":103,"phases":1020,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":1021,"interventions":1022},[88],[977],[925,941,979],{"trials":1024,"activeCount":14},[1025],{"nctId":983,"briefTitle":984,"status":103,"phases":1026,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":1027,"interventions":1028},[89],[991],[925,941,993,994],{"trials":1030,"activeCount":14},[],{"trials":1032,"activeCount":14},[],{"intervention":1034,"totalTrials":31,"cells":1035},"RPH-104 80 mg",{"EARLY_PHASE1":1036,"PHASE1":1038,"PHASE2":1052,"PHASE3":1065,"PHASE4":1078,"NA":1080},{"trials":1037,"activeCount":14},[],{"trials":1039,"activeCount":14},[1040],{"nctId":1041,"briefTitle":1042,"status":103,"phases":1043,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":1048,"interventions":1049},"NCT07206043","Pharmacokinetics, Safety and Immunogenicity of RPH-104 at a New Dosage and Different Doses Via Single Subcutaneous and Intravenous Administration in Healthy Volunteers",[87],"2025-02-27","2025-07-25","2024-12-03",130,[27],[1034,1050,1051,1051,1034,1034],"RPH-104 160 mg","RPH-104 320 mg",{"trials":1053,"activeCount":14},[1054],{"nctId":1055,"briefTitle":1056,"status":103,"phases":1057,"primaryCompletion":1058,"completion":1059,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1064},"NCT04463251","Study to Evaluate the Effect on Parameters of Systemic Inflammation and Disease Outcomes and Safety of RPH-104 in Subjects With Acute ST-elevation Myocardial Infarction",[88],"2021-11-03","2022-10-10","2020-12-07",102,[1063],"Acute ST Segment Elevation Myocardial Infarction",[1034],{"trials":1066,"activeCount":14},[1067],{"nctId":1068,"briefTitle":1069,"status":103,"phases":1070,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":1075,"interventions":1076},"NCT04380519","Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)",[88,89],"2020-07-10","2020-07-24","2020-04-23",372,[20],[1034,1077],"Olokizumab 64 mg",{"trials":1079,"activeCount":14},[],{"trials":1081,"activeCount":14},[],{"intervention":910,"totalTrials":130,"cells":1083},{"EARLY_PHASE1":1084,"PHASE1":1086,"PHASE2":1088,"PHASE3":1090,"PHASE4":1100,"NA":1102},{"trials":1085,"activeCount":14},[],{"trials":1087,"activeCount":14},[],{"trials":1089,"activeCount":14},[],{"trials":1091,"activeCount":14},[1092,1096],{"nctId":902,"briefTitle":903,"status":103,"phases":1093,"primaryCompletion":905,"completion":905,"start":906,"enrollment":907,"conditions":1094,"interventions":1095},[89],[30,22],[910,723],{"nctId":912,"briefTitle":913,"status":103,"phases":1097,"primaryCompletion":915,"completion":905,"start":916,"enrollment":917,"conditions":1098,"interventions":1099},[89],[22,850],[910,723],{"trials":1101,"activeCount":14},[],{"trials":1103,"activeCount":14},[],{"intervention":1077,"totalTrials":130,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1112,"PHASE4":1127,"NA":1129},{"trials":1107,"activeCount":14},[],{"trials":1109,"activeCount":14},[],{"trials":1111,"activeCount":14},[],{"trials":1113,"activeCount":14},[1114,1118],{"nctId":1068,"briefTitle":1069,"status":103,"phases":1115,"primaryCompletion":1071,"completion":1072,"start":1073,"enrollment":1074,"conditions":1116,"interventions":1117},[88,89],[20],[1034,1077],{"nctId":1119,"briefTitle":1120,"status":159,"phases":1121,"primaryCompletion":1122,"completion":1123,"start":1124,"enrollment":14,"conditions":1125,"interventions":1126},"NCT04452474","Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19).",[88,89],"2020-11-16","2021-01-29","2020-06-30",[20],[1077],{"trials":1128,"activeCount":14},[],{"trials":1130,"activeCount":14},[],{"intervention":1132,"totalTrials":130,"cells":1133},"RPH-075",{"EARLY_PHASE1":1134,"PHASE1":1136,"PHASE2":1151,"PHASE3":1153,"PHASE4":1164,"NA":1166},{"trials":1135,"activeCount":14},[],{"trials":1137,"activeCount":14},[1138],{"nctId":1139,"briefTitle":1140,"status":727,"phases":1141,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":1145,"conditions":1146,"interventions":1149},"NCT06307093","Study Comparing the Pharmacokinetics, Safety, and Efficacy of RPH-075 and Keytruda® in Patients With Malignant Neoplasms",[87],"2023-12-11","2025-07","2023-03-01",90,[1147,1148,35],"Skin Melanoma","Squamous Non-small-cell Lung Cancer",[1132,1150],"Keytruda®",{"trials":1152,"activeCount":14},[],{"trials":1154,"activeCount":14},[1155],{"nctId":1156,"briefTitle":1157,"status":727,"phases":1158,"primaryCompletion":1159,"completion":55,"start":1160,"enrollment":1161,"conditions":1162,"interventions":1163},"NCT06320353","Study сomparing the Efficacy and Safety of RPH-075 and Keytruda® in Patients With Unresectable or Metastatic Skin Melanoma",[89],"2024-06","2023-09-27",266,[1147],[1132,1150],{"trials":1165,"activeCount":14},[],{"trials":1167,"activeCount":14},[],{"intervention":1150,"totalTrials":130,"cells":1169},{"EARLY_PHASE1":1170,"PHASE1":1172,"PHASE2":1178,"PHASE3":1180,"PHASE4":1186,"NA":1188},{"trials":1171,"activeCount":14},[],{"trials":1173,"activeCount":14},[1174],{"nctId":1139,"briefTitle":1140,"status":727,"phases":1175,"primaryCompletion":1142,"completion":1143,"start":1144,"enrollment":1145,"conditions":1176,"interventions":1177},[87],[1147,1148,35],[1132,1150],{"trials":1179,"activeCount":14},[],{"trials":1181,"activeCount":14},[1182],{"nctId":1156,"briefTitle":1157,"status":727,"phases":1183,"primaryCompletion":1159,"completion":55,"start":1160,"enrollment":1161,"conditions":1184,"interventions":1185},[89],[1147],[1132,1150],{"trials":1187,"activeCount":14},[],{"trials":1189,"activeCount":14},[],{"intervention":1191,"totalTrials":174,"cells":1192},"Odelepan",{"EARLY_PHASE1":1193,"PHASE1":1195,"PHASE2":1197,"PHASE3":1199,"PHASE4":1212,"NA":1214},{"trials":1194,"activeCount":14},[],{"trials":1196,"activeCount":14},[],{"trials":1198,"activeCount":14},[],{"trials":1200,"activeCount":14},[1201],{"nctId":1202,"briefTitle":1203,"status":103,"phases":1204,"primaryCompletion":1205,"completion":1206,"start":1207,"enrollment":1208,"conditions":1209,"interventions":1211},"NCT03663374","Efficacy and Safety Evaluating Study of Odelepran for the Use in Patient With Alcohol Dependence",[89],"2016-04-16","2016-05-14","2014-11-18",644,[1210],"Alcohol Dependence",[1191],{"trials":1213,"activeCount":14},[],{"trials":1215,"activeCount":14},[],{"intervention":1217,"totalTrials":174,"cells":1218},"Uritos®",{"EARLY_PHASE1":1219,"PHASE1":1221,"PHASE2":1223,"PHASE3":1225,"PHASE4":1239,"NA":1241},{"trials":1220,"activeCount":14},[],{"trials":1222,"activeCount":14},[],{"trials":1224,"activeCount":14},[],{"trials":1226,"activeCount":14},[1227],{"nctId":1228,"briefTitle":1229,"status":103,"phases":1230,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1237},"NCT03575702","Efficacy and Safety Evaluating Study to Compare Uritos® (Imidafenacin) and Urotol® (Tolterodine) for Treatment of Overactive Bladder.",[89],"2017-08-01","2017-09-01","2016-07-18",300,[1236],"Overactive Bladder",[1217,1238],"Urotol®",{"trials":1240,"activeCount":14},[],{"trials":1242,"activeCount":14},[],{"intervention":1238,"totalTrials":174,"cells":1244},{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1251,"PHASE4":1257,"NA":1259},{"trials":1246,"activeCount":14},[],{"trials":1248,"activeCount":14},[],{"trials":1250,"activeCount":14},[],{"trials":1252,"activeCount":14},[1253],{"nctId":1228,"briefTitle":1229,"status":103,"phases":1254,"primaryCompletion":1231,"completion":1232,"start":1233,"enrollment":1234,"conditions":1255,"interventions":1256},[89],[1236],[1217,1238],{"trials":1258,"activeCount":14},[],{"trials":1260,"activeCount":14},[],{"intervention":1262,"totalTrials":174,"cells":1263},"Fimasartan",{"EARLY_PHASE1":1264,"PHASE1":1266,"PHASE2":1268,"PHASE3":1270,"PHASE4":1283,"NA":1285},{"trials":1265,"activeCount":14},[],{"trials":1267,"activeCount":14},[],{"trials":1269,"activeCount":14},[],{"trials":1271,"activeCount":14},[1272],{"nctId":1273,"briefTitle":1274,"status":103,"phases":1275,"primaryCompletion":1276,"completion":1276,"start":1277,"enrollment":1278,"conditions":1279,"interventions":1281},"NCT02248961","Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension",[89],"2015-08","2014-05",179,[1280],"Arterial Hypertension",[1262,1282],"Losartan",{"trials":1284,"activeCount":14},[],{"trials":1286,"activeCount":14},[],{"intervention":1282,"totalTrials":174,"cells":1288},{"EARLY_PHASE1":1289,"PHASE1":1291,"PHASE2":1293,"PHASE3":1295,"PHASE4":1301,"NA":1303},{"trials":1290,"activeCount":14},[],{"trials":1292,"activeCount":14},[],{"trials":1294,"activeCount":14},[],{"trials":1296,"activeCount":14},[1297],{"nctId":1273,"briefTitle":1274,"status":103,"phases":1298,"primaryCompletion":1276,"completion":1276,"start":1277,"enrollment":1278,"conditions":1299,"interventions":1300},[89],[1280],[1262,1282],{"trials":1302,"activeCount":14},[],{"trials":1304,"activeCount":14},[],{"intervention":1306,"totalTrials":174,"cells":1307},"Olokizumab 64 mg SC q4w",{"EARLY_PHASE1":1308,"PHASE1":1310,"PHASE2":1312,"PHASE3":1314,"PHASE4":1327,"NA":1329},{"trials":1309,"activeCount":14},[],{"trials":1311,"activeCount":14},[],{"trials":1313,"activeCount":14},[],{"trials":1315,"activeCount":14},[1316],{"nctId":1317,"briefTitle":1318,"status":103,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1324},"NCT03120949","Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis",[89],"2021-09-01","2017-07-04",2106,[25],[1306,1325,1326],"Olokizumab 64 mg SC q2w","Concomitant treatment",{"trials":1328,"activeCount":14},[],{"trials":1330,"activeCount":14},[],{"intervention":1325,"totalTrials":174,"cells":1332},{"EARLY_PHASE1":1333,"PHASE1":1335,"PHASE2":1337,"PHASE3":1339,"PHASE4":1345,"NA":1347},{"trials":1334,"activeCount":14},[],{"trials":1336,"activeCount":14},[],{"trials":1338,"activeCount":14},[],{"trials":1340,"activeCount":14},[1341],{"nctId":1317,"briefTitle":1318,"status":103,"phases":1342,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":1322,"conditions":1343,"interventions":1344},[89],[25],[1306,1325,1326],{"trials":1346,"activeCount":14},[],{"trials":1348,"activeCount":14},[],{"intervention":1326,"totalTrials":174,"cells":1350},{"EARLY_PHASE1":1351,"PHASE1":1353,"PHASE2":1355,"PHASE3":1357,"PHASE4":1363,"NA":1365},{"trials":1352,"activeCount":14},[],{"trials":1354,"activeCount":14},[],{"trials":1356,"activeCount":14},[],{"trials":1358,"activeCount":14},[1359],{"nctId":1317,"briefTitle":1318,"status":103,"phases":1360,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":1322,"conditions":1361,"interventions":1362},[89],[25],[1306,1325,1326],{"trials":1364,"activeCount":14},[],{"trials":1366,"activeCount":14},[],{"intervention":993,"totalTrials":174,"cells":1368},{"EARLY_PHASE1":1369,"PHASE1":1371,"PHASE2":1373,"PHASE3":1375,"PHASE4":1381,"NA":1383},{"trials":1370,"activeCount":14},[],{"trials":1372,"activeCount":14},[],{"trials":1374,"activeCount":14},[],{"trials":1376,"activeCount":14},[1377],{"nctId":983,"briefTitle":984,"status":103,"phases":1378,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":1379,"interventions":1380},[89],[991],[925,941,993,994],{"trials":1382,"activeCount":14},[],{"trials":1384,"activeCount":14},[],{"intervention":994,"totalTrials":174,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1399,"NA":1401},{"trials":1388,"activeCount":14},[],{"trials":1390,"activeCount":14},[],{"trials":1392,"activeCount":14},[],{"trials":1394,"activeCount":14},[1395],{"nctId":983,"briefTitle":984,"status":103,"phases":1396,"primaryCompletion":986,"completion":987,"start":988,"enrollment":989,"conditions":1397,"interventions":1398},[89],[991],[925,941,993,994],{"trials":1400,"activeCount":14},[],{"trials":1402,"activeCount":14},[],{"intervention":1404,"totalTrials":174,"cells":1405},"Nemonoxacin",{"EARLY_PHASE1":1406,"PHASE1":1408,"PHASE2":1410,"PHASE3":1412,"PHASE4":1426,"NA":1428},{"trials":1407,"activeCount":14},[],{"trials":1409,"activeCount":14},[],{"trials":1411,"activeCount":14},[],{"trials":1413,"activeCount":14},[1414],{"nctId":1415,"briefTitle":1416,"status":103,"phases":1417,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1422,"interventions":1424},"NCT03551210","Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia",[89],"2017-12-13","2017-12-26","2016-05-04",342,[1423],"Pneumonia, Bacterial",[1404,1404,1425,1425],"Tavanic",{"trials":1427,"activeCount":14},[],{"trials":1429,"activeCount":14},[],{"intervention":1425,"totalTrials":174,"cells":1431},{"EARLY_PHASE1":1432,"PHASE1":1434,"PHASE2":1436,"PHASE3":1438,"PHASE4":1444,"NA":1446},{"trials":1433,"activeCount":14},[],{"trials":1435,"activeCount":14},[],{"trials":1437,"activeCount":14},[],{"trials":1439,"activeCount":14},[1440],{"nctId":1415,"briefTitle":1416,"status":103,"phases":1441,"primaryCompletion":1418,"completion":1419,"start":1420,"enrollment":1421,"conditions":1442,"interventions":1443},[89],[1423],[1404,1404,1425,1425],{"trials":1445,"activeCount":14},[],{"trials":1447,"activeCount":14},[],{"intervention":1449,"totalTrials":174,"cells":1450},"Olokizumab 64mg q4w",{"EARLY_PHASE1":1451,"PHASE1":1453,"PHASE2":1455,"PHASE3":1457,"PHASE4":1471,"NA":1473},{"trials":1452,"activeCount":14},[],{"trials":1454,"activeCount":14},[],{"trials":1456,"activeCount":14},[],{"trials":1458,"activeCount":14},[1459],{"nctId":1460,"briefTitle":1461,"status":103,"phases":1462,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":1466,"conditions":1467,"interventions":1468},"NCT02760407","Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease",[89],"2019-08-02","2019-11-05","2016-06-06",1648,[25],[1449,1469,1470],"Olokizumab 64mg q2w","Adalimumab 40mg q2w",{"trials":1472,"activeCount":14},[],{"trials":1474,"activeCount":14},[],{"intervention":1469,"totalTrials":174,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1489,"NA":1491},{"trials":1478,"activeCount":14},[],{"trials":1480,"activeCount":14},[],{"trials":1482,"activeCount":14},[],{"trials":1484,"activeCount":14},[1485],{"nctId":1460,"briefTitle":1461,"status":103,"phases":1486,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":1466,"conditions":1487,"interventions":1488},[89],[25],[1449,1469,1470],{"trials":1490,"activeCount":14},[],{"trials":1492,"activeCount":14},[],{"intervention":1470,"totalTrials":174,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1507,"NA":1509},{"trials":1496,"activeCount":14},[],{"trials":1498,"activeCount":14},[],{"trials":1500,"activeCount":14},[],{"trials":1502,"activeCount":14},[1503],{"nctId":1460,"briefTitle":1461,"status":103,"phases":1504,"primaryCompletion":1463,"completion":1464,"start":1465,"enrollment":1466,"conditions":1505,"interventions":1506},[89],[25],[1449,1469,1470],{"trials":1508,"activeCount":14},[],{"trials":1510,"activeCount":14},[],{"intervention":1512,"totalTrials":174,"cells":1513},"Favipiravir",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1534,"NA":1536},{"trials":1515,"activeCount":14},[],{"trials":1517,"activeCount":14},[],{"trials":1519,"activeCount":14},[],{"trials":1521,"activeCount":14},[1522],{"nctId":1523,"briefTitle":1524,"status":103,"phases":1525,"primaryCompletion":1526,"completion":1527,"start":1528,"enrollment":1529,"conditions":1530,"interventions":1531},"NCT04501783","Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19",[89],"2020-07-29","2020-08-04","2020-05-20",168,[20],[1512,1532,1533],"Standard of care","standard concomitant therapy",{"trials":1535,"activeCount":14},[],{"trials":1537,"activeCount":14},[],{"intervention":1532,"totalTrials":174,"cells":1539},{"EARLY_PHASE1":1540,"PHASE1":1542,"PHASE2":1544,"PHASE3":1546,"PHASE4":1552,"NA":1554},{"trials":1541,"activeCount":14},[],{"trials":1543,"activeCount":14},[],{"trials":1545,"activeCount":14},[],{"trials":1547,"activeCount":14},[1548],{"nctId":1523,"briefTitle":1524,"status":103,"phases":1549,"primaryCompletion":1526,"completion":1527,"start":1528,"enrollment":1529,"conditions":1550,"interventions":1551},[89],[20],[1512,1532,1533],{"trials":1553,"activeCount":14},[],{"trials":1555,"activeCount":14},[],{"intervention":1533,"totalTrials":174,"cells":1557},{"EARLY_PHASE1":1558,"PHASE1":1560,"PHASE2":1562,"PHASE3":1564,"PHASE4":1570,"NA":1572},{"trials":1559,"activeCount":14},[],{"trials":1561,"activeCount":14},[],{"trials":1563,"activeCount":14},[],{"trials":1565,"activeCount":14},[1566],{"nctId":1523,"briefTitle":1524,"status":103,"phases":1567,"primaryCompletion":1526,"completion":1527,"start":1528,"enrollment":1529,"conditions":1568,"interventions":1569},[89],[20],[1512,1532,1533],{"trials":1571,"activeCount":14},[],{"trials":1573,"activeCount":14},[],{"intervention":873,"totalTrials":174,"cells":1575},{"EARLY_PHASE1":1576,"PHASE1":1578,"PHASE2":1580,"PHASE3":1582,"PHASE4":1588,"NA":1590},{"trials":1577,"activeCount":14},[],{"trials":1579,"activeCount":14},[],{"trials":1581,"activeCount":14},[],{"trials":1583,"activeCount":14},[1584],{"nctId":863,"briefTitle":864,"status":758,"phases":1585,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":1586,"interventions":1587},[89],[871],[252,873,874],{"trials":1589,"activeCount":14},[],{"trials":1591,"activeCount":14},[],{"intervention":874,"totalTrials":174,"cells":1593},{"EARLY_PHASE1":1594,"PHASE1":1596,"PHASE2":1598,"PHASE3":1600,"PHASE4":1606,"NA":1608},{"trials":1595,"activeCount":14},[],{"trials":1597,"activeCount":14},[],{"trials":1599,"activeCount":14},[],{"trials":1601,"activeCount":14},[1602],{"nctId":863,"briefTitle":864,"status":758,"phases":1603,"primaryCompletion":866,"completion":867,"start":868,"enrollment":869,"conditions":1604,"interventions":1605},[89],[871],[252,873,874],{"trials":1607,"activeCount":14},[],{"trials":1609,"activeCount":14},[],{"intervention":1611,"totalTrials":174,"cells":1612},"Remimazolam",{"EARLY_PHASE1":1613,"PHASE1":1615,"PHASE2":1617,"PHASE3":1619,"PHASE4":1635,"NA":1637},{"trials":1614,"activeCount":14},[],{"trials":1616,"activeCount":14},[],{"trials":1618,"activeCount":14},[],{"trials":1620,"activeCount":14},[1621],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1624,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1629,"interventions":1631},"NCT03669484","Comparative Clinical Study of Efficacy and Safety of Remimazolam and Propofol in Patients Undergoing Elective Surgery Under General Anaesthesia",[89],"2018-05-15","2018-05-24","2017-08-22",150,[1630],"General Anaesthesia",[1611,1632,1633,1634],"Propofol","Fentanyl","Rocuronium bromide",{"trials":1636,"activeCount":14},[],{"trials":1638,"activeCount":14},[],{"intervention":1632,"totalTrials":174,"cells":1640},{"EARLY_PHASE1":1641,"PHASE1":1643,"PHASE2":1645,"PHASE3":1647,"PHASE4":1653,"NA":1655},{"trials":1642,"activeCount":14},[],{"trials":1644,"activeCount":14},[],{"trials":1646,"activeCount":14},[],{"trials":1648,"activeCount":14},[1649],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1650,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1651,"interventions":1652},[89],[1630],[1611,1632,1633,1634],{"trials":1654,"activeCount":14},[],{"trials":1656,"activeCount":14},[],{"intervention":1633,"totalTrials":174,"cells":1658},{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1671,"NA":1673},{"trials":1660,"activeCount":14},[],{"trials":1662,"activeCount":14},[],{"trials":1664,"activeCount":14},[],{"trials":1666,"activeCount":14},[1667],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1668,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1669,"interventions":1670},[89],[1630],[1611,1632,1633,1634],{"trials":1672,"activeCount":14},[],{"trials":1674,"activeCount":14},[],{"intervention":1634,"totalTrials":174,"cells":1676},{"EARLY_PHASE1":1677,"PHASE1":1679,"PHASE2":1681,"PHASE3":1683,"PHASE4":1689,"NA":1691},{"trials":1678,"activeCount":14},[],{"trials":1680,"activeCount":14},[],{"trials":1682,"activeCount":14},[],{"trials":1684,"activeCount":14},[1685],{"nctId":1622,"briefTitle":1623,"status":103,"phases":1686,"primaryCompletion":1625,"completion":1626,"start":1627,"enrollment":1628,"conditions":1687,"interventions":1688},[89],[1630],[1611,1632,1633,1634],{"trials":1690,"activeCount":14},[],{"trials":1692,"activeCount":14},[],{"intervention":1694,"totalTrials":31,"cells":1695},"AZD1222",{"EARLY_PHASE1":1696,"PHASE1":1698,"PHASE2":1700,"PHASE3":1730,"PHASE4":1732,"NA":1734},{"trials":1697,"activeCount":14},[],{"trials":1699,"activeCount":14},[],{"trials":1701,"activeCount":14},[1702,1713,1722],{"nctId":1703,"briefTitle":1704,"status":103,"phases":1705,"primaryCompletion":1706,"completion":1707,"start":1708,"enrollment":1709,"conditions":1710,"interventions":1711},"NCT04684446","Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19",[87,88],"2021-11-26","2022-03-29","2021-09-15",100,[20],[1694,1712],"rAd26-S",{"nctId":1714,"briefTitle":1715,"status":103,"phases":1716,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1709,"conditions":1720,"interventions":1721},"NCT04686773","Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 Prevention",[88],"2021-10-30","2022-03-18","2021-03-05",[20],[1694,1712],{"nctId":1723,"briefTitle":1724,"status":103,"phases":1725,"primaryCompletion":1707,"completion":1726,"start":1727,"enrollment":1709,"conditions":1728,"interventions":1729},"NCT04760730","Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)",[87,88],"2022-07-26","2021-07-13",[20],[1694,1712],{"trials":1731,"activeCount":14},[],{"trials":1733,"activeCount":14},[],{"trials":1735,"activeCount":14},[],{"intervention":1712,"totalTrials":31,"cells":1737},{"EARLY_PHASE1":1738,"PHASE1":1740,"PHASE2":1742,"PHASE3":1756,"PHASE4":1758,"NA":1760},{"trials":1739,"activeCount":14},[],{"trials":1741,"activeCount":14},[],{"trials":1743,"activeCount":14},[1744,1748,1752],{"nctId":1703,"briefTitle":1704,"status":103,"phases":1745,"primaryCompletion":1706,"completion":1707,"start":1708,"enrollment":1709,"conditions":1746,"interventions":1747},[87,88],[20],[1694,1712],{"nctId":1714,"briefTitle":1715,"status":103,"phases":1749,"primaryCompletion":1717,"completion":1718,"start":1719,"enrollment":1709,"conditions":1750,"interventions":1751},[88],[20],[1694,1712],{"nctId":1723,"briefTitle":1724,"status":103,"phases":1753,"primaryCompletion":1707,"completion":1726,"start":1727,"enrollment":1709,"conditions":1754,"interventions":1755},[87,88],[20],[1694,1712],{"trials":1757,"activeCount":14},[],{"trials":1759,"activeCount":14},[],{"trials":1761,"activeCount":14},[],{"intervention":1763,"totalTrials":174,"cells":1764},"Ixabepilone, 40 mg\u002Fm^2 + Capecitabine, 1000 mg\u002Fm^2",{"EARLY_PHASE1":1765,"PHASE1":1767,"PHASE2":1769,"PHASE3":1782,"PHASE4":1784,"NA":1786},{"trials":1766,"activeCount":14},[],{"trials":1768,"activeCount":14},[],{"trials":1770,"activeCount":14},[1771],{"nctId":1772,"briefTitle":1773,"status":758,"phases":1774,"primaryCompletion":1775,"completion":1775,"start":205,"enrollment":1776,"conditions":1777,"interventions":1779},"NCT00546364","Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer",[88],"2010-03",62,[1778],"Breast Neoplasms",[1763,1780,1781],"Ixabepilone, 32 mg\u002Fm^2 + Capecitabine, 1000 mg\u002Fm^2","Docetaxel, 75 mg\u002Fm^2 + Capecitabine, 1000 mg\u002Fm^2",{"trials":1783,"activeCount":14},[],{"trials":1785,"activeCount":14},[],{"trials":1787,"activeCount":14},[],{"intervention":1780,"totalTrials":174,"cells":1789},{"EARLY_PHASE1":1790,"PHASE1":1792,"PHASE2":1794,"PHASE3":1800,"PHASE4":1802,"NA":1804},{"trials":1791,"activeCount":14},[],{"trials":1793,"activeCount":14},[],{"trials":1795,"activeCount":14},[1796],{"nctId":1772,"briefTitle":1773,"status":758,"phases":1797,"primaryCompletion":1775,"completion":1775,"start":205,"enrollment":1776,"conditions":1798,"interventions":1799},[88],[1778],[1763,1780,1781],{"trials":1801,"activeCount":14},[],{"trials":1803,"activeCount":14},[],{"trials":1805,"activeCount":14},[],{"intervention":1781,"totalTrials":174,"cells":1807},{"EARLY_PHASE1":1808,"PHASE1":1810,"PHASE2":1812,"PHASE3":1818,"PHASE4":1820,"NA":1822},{"trials":1809,"activeCount":14},[],{"trials":1811,"activeCount":14},[],{"trials":1813,"activeCount":14},[1814],{"nctId":1772,"briefTitle":1773,"status":758,"phases":1815,"primaryCompletion":1775,"completion":1775,"start":205,"enrollment":1776,"conditions":1816,"interventions":1817},[88],[1778],[1763,1780,1781],{"trials":1819,"activeCount":14},[],{"trials":1821,"activeCount":14},[],{"trials":1823,"activeCount":14},[],{"intervention":1825,"totalTrials":174,"cells":1826},"Ixabepilone, 16 mg\u002Fm^2 + Bevacizumab, 10 mg\u002Fkg",{"EARLY_PHASE1":1827,"PHASE1":1829,"PHASE2":1831,"PHASE3":1843,"PHASE4":1845,"NA":1847},{"trials":1828,"activeCount":14},[],{"trials":1830,"activeCount":14},[],{"trials":1832,"activeCount":14},[1833],{"nctId":1834,"briefTitle":1835,"status":103,"phases":1836,"primaryCompletion":839,"completion":839,"start":1837,"enrollment":1838,"conditions":1839,"interventions":1840},"NCT00370552","A Trial of 2 Schedules of Ixabepilone Plus Bevacizumab and Paclitaxel Plus Bevacizumab for Breast Cancer",[88],"2007-03",136,[17],[1825,1841,1842],"Ixabepilone, 40 mg\u002Fm^2 + Bevacizumab, 15 mg\u002Fkg","Paclitaxel, 90 mg\u002Fm^2 + Bevacizumab, 10 mg\u002Fkg",{"trials":1844,"activeCount":14},[],{"trials":1846,"activeCount":14},[],{"trials":1848,"activeCount":14},[],{"intervention":1841,"totalTrials":174,"cells":1850},{"EARLY_PHASE1":1851,"PHASE1":1853,"PHASE2":1855,"PHASE3":1861,"PHASE4":1863,"NA":1865},{"trials":1852,"activeCount":14},[],{"trials":1854,"activeCount":14},[],{"trials":1856,"activeCount":14},[1857],{"nctId":1834,"briefTitle":1835,"status":103,"phases":1858,"primaryCompletion":839,"completion":839,"start":1837,"enrollment":1838,"conditions":1859,"interventions":1860},[88],[17],[1825,1841,1842],{"trials":1862,"activeCount":14},[],{"trials":1864,"activeCount":14},[],{"trials":1866,"activeCount":14},[],{"intervention":1842,"totalTrials":174,"cells":1868},{"EARLY_PHASE1":1869,"PHASE1":1871,"PHASE2":1873,"PHASE3":1879,"PHASE4":1881,"NA":1883},{"trials":1870,"activeCount":14},[],{"trials":1872,"activeCount":14},[],{"trials":1874,"activeCount":14},[1875],{"nctId":1834,"briefTitle":1835,"status":103,"phases":1876,"primaryCompletion":839,"completion":839,"start":1837,"enrollment":1838,"conditions":1877,"interventions":1878},[88],[17],[1825,1841,1842],{"trials":1880,"activeCount":14},[],{"trials":1882,"activeCount":14},[],{"trials":1884,"activeCount":14},[],{"intervention":1886,"totalTrials":174,"cells":1887},"Ixabepilone, 32 mg\u002Fm^2",{"EARLY_PHASE1":1888,"PHASE1":1890,"PHASE2":1892,"PHASE3":1907,"PHASE4":1909,"NA":1911},{"trials":1889,"activeCount":14},[],{"trials":1891,"activeCount":14},[],{"trials":1893,"activeCount":14},[1894],{"nctId":1895,"briefTitle":1896,"status":103,"phases":1897,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1901,"conditions":1902,"interventions":1904},"NCT00723957","A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer",[88],"2010-05","2011-08","2008-12",260,[1903],"Advanced\u002FMetastatic Non-Small Cell Lung Cancer",[1886,1905,1906],"Paclitaxel, 200 mg\u002Fm^2","Carboplatin",{"trials":1908,"activeCount":14},[],{"trials":1910,"activeCount":14},[],{"trials":1912,"activeCount":14},[],{"intervention":1905,"totalTrials":174,"cells":1914},{"EARLY_PHASE1":1915,"PHASE1":1917,"PHASE2":1919,"PHASE3":1925,"PHASE4":1927,"NA":1929},{"trials":1916,"activeCount":14},[],{"trials":1918,"activeCount":14},[],{"trials":1920,"activeCount":14},[1921],{"nctId":1895,"briefTitle":1896,"status":103,"phases":1922,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1901,"conditions":1923,"interventions":1924},[88],[1903],[1886,1905,1906],{"trials":1926,"activeCount":14},[],{"trials":1928,"activeCount":14},[],{"trials":1930,"activeCount":14},[],{"intervention":1906,"totalTrials":174,"cells":1932},{"EARLY_PHASE1":1933,"PHASE1":1935,"PHASE2":1937,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1934,"activeCount":14},[],{"trials":1936,"activeCount":14},[],{"trials":1938,"activeCount":14},[1939],{"nctId":1895,"briefTitle":1896,"status":103,"phases":1940,"primaryCompletion":1898,"completion":1899,"start":1900,"enrollment":1901,"conditions":1941,"interventions":1942},[88],[1903],[1886,1905,1906],{"trials":1944,"activeCount":14},[],{"trials":1946,"activeCount":14},[],{"trials":1948,"activeCount":14},[],{"intervention":1950,"totalTrials":174,"cells":1951},"RPH - 104",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1956,"PHASE3":1970,"PHASE4":1972,"NA":1974},{"trials":1953,"activeCount":14},[],{"trials":1955,"activeCount":14},[],{"trials":1957,"activeCount":14},[1958],{"nctId":1959,"briefTitle":1960,"status":758,"phases":1961,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1966,"interventions":1968},"NCT04067492","Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Evaluation of RPH-104 Administered at Different Doses to Patients With Acute Gout Attack",[88],"2020-03-16","2020-05-12","2018-03-26",47,[1967],"Gout Attack",[1950,1969],"Voltaren®",{"trials":1971,"activeCount":14},[],{"trials":1973,"activeCount":14},[],{"trials":1975,"activeCount":14},[],{"intervention":1969,"totalTrials":174,"cells":1977},{"EARLY_PHASE1":1978,"PHASE1":1980,"PHASE2":1982,"PHASE3":1988,"PHASE4":1990,"NA":1992},{"trials":1979,"activeCount":14},[],{"trials":1981,"activeCount":14},[],{"trials":1983,"activeCount":14},[1984],{"nctId":1959,"briefTitle":1960,"status":758,"phases":1985,"primaryCompletion":1962,"completion":1963,"start":1964,"enrollment":1965,"conditions":1986,"interventions":1987},[88],[1967],[1950,1969],{"trials":1989,"activeCount":14},[],{"trials":1991,"activeCount":14},[],{"trials":1993,"activeCount":14},[],{"intervention":803,"totalTrials":174,"cells":1995},{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2006,"PHASE4":2008,"NA":2010},{"trials":1997,"activeCount":14},[],{"trials":1999,"activeCount":14},[],{"trials":2001,"activeCount":14},[2002],{"nctId":795,"briefTitle":796,"status":103,"phases":2003,"primaryCompletion":760,"completion":760,"start":798,"enrollment":799,"conditions":2004,"interventions":2005},[88],[801],[252,803],{"trials":2007,"activeCount":14},[],{"trials":2009,"activeCount":14},[],{"trials":2011,"activeCount":14},[],{"intervention":967,"totalTrials":174,"cells":2013},{"EARLY_PHASE1":2014,"PHASE1":2016,"PHASE2":2018,"PHASE3":2024,"PHASE4":2026,"NA":2028},{"trials":2015,"activeCount":14},[],{"trials":2017,"activeCount":14},[],{"trials":2019,"activeCount":14},[2020],{"nctId":957,"briefTitle":958,"status":103,"phases":2021,"primaryCompletion":960,"completion":961,"start":962,"enrollment":963,"conditions":2022,"interventions":2023},[88],[965],[925,941,967],{"trials":2025,"activeCount":14},[],{"trials":2027,"activeCount":14},[],{"trials":2029,"activeCount":14},[],{"intervention":2031,"totalTrials":174,"cells":2032},"Epothilone",{"EARLY_PHASE1":2033,"PHASE1":2035,"PHASE2":2037,"PHASE3":2047,"PHASE4":2049,"NA":2051},{"trials":2034,"activeCount":14},[],{"trials":2036,"activeCount":14},[],{"trials":2038,"activeCount":14},[2039],{"nctId":2040,"briefTitle":2041,"status":103,"phases":2042,"primaryCompletion":701,"completion":701,"start":2043,"conditions":2044,"interventions":2046},"NCT00035516","A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy",[88],"2001-02",[2045],"Carcinoma, Non-small-cell Lung",[2031],{"trials":2048,"activeCount":14},[],{"trials":2050,"activeCount":14},[],{"trials":2052,"activeCount":14},[],{"intervention":2054,"totalTrials":174,"cells":2055},"80 mg RPH-104",{"EARLY_PHASE1":2056,"PHASE1":2058,"PHASE2":2060,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2057,"activeCount":14},[],{"trials":2059,"activeCount":14},[],{"trials":2061,"activeCount":14},[2062],{"nctId":2063,"briefTitle":2064,"status":159,"phases":2065,"primaryCompletion":2066,"completion":2067,"start":2068,"enrollment":14,"conditions":2069,"interventions":2072},"NCT04213274","Study of the Efficacy and Safety of RPH-104 in Adult Subjects With Schnitzler Syndrome",[88],"2023-08","2024-01","2023-05",[2070,2071],"Schnitzler Syndrome","Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)",[2054],{"trials":2074,"activeCount":14},[],{"trials":2076,"activeCount":14},[],{"trials":2078,"activeCount":14},[],{"intervention":834,"totalTrials":174,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2085,"PHASE3":2091,"PHASE4":2093,"NA":2095},{"trials":2082,"activeCount":14},[],{"trials":2084,"activeCount":14},[],{"trials":2086,"activeCount":14},[2087],{"nctId":824,"briefTitle":825,"status":103,"phases":2088,"primaryCompletion":827,"completion":828,"start":829,"enrollment":830,"conditions":2089,"interventions":2090},[88],[832,17],[209,834],{"trials":2092,"activeCount":14},[],{"trials":2094,"activeCount":14},[],{"trials":2096,"activeCount":14},[],{"intervention":979,"totalTrials":174,"cells":2098},{"EARLY_PHASE1":2099,"PHASE1":2101,"PHASE2":2103,"PHASE3":2109,"PHASE4":2111,"NA":2113},{"trials":2100,"activeCount":14},[],{"trials":2102,"activeCount":14},[],{"trials":2104,"activeCount":14},[2105],{"nctId":969,"briefTitle":970,"status":103,"phases":2106,"primaryCompletion":972,"completion":973,"start":974,"enrollment":975,"conditions":2107,"interventions":2108},[88],[977],[925,941,979],{"trials":2110,"activeCount":14},[],{"trials":2112,"activeCount":14},[],{"trials":2114,"activeCount":14},[],{"intervention":942,"totalTrials":174,"cells":2116},{"EARLY_PHASE1":2117,"PHASE1":2119,"PHASE2":2125,"PHASE3":2127,"PHASE4":2129,"NA":2131},{"trials":2118,"activeCount":14},[],{"trials":2120,"activeCount":14},[2121],{"nctId":932,"briefTitle":933,"status":103,"phases":2122,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":2123,"interventions":2124},[87],[27],[925,941,942,943],{"trials":2126,"activeCount":14},[],{"trials":2128,"activeCount":14},[],{"trials":2130,"activeCount":14},[],{"trials":2132,"activeCount":14},[],{"intervention":943,"totalTrials":174,"cells":2134},{"EARLY_PHASE1":2135,"PHASE1":2137,"PHASE2":2143,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2136,"activeCount":14},[],{"trials":2138,"activeCount":14},[2139],{"nctId":932,"briefTitle":933,"status":103,"phases":2140,"primaryCompletion":935,"completion":936,"start":937,"enrollment":938,"conditions":2141,"interventions":2142},[87],[27],[925,941,942,943],{"trials":2144,"activeCount":14},[],{"trials":2146,"activeCount":14},[],{"trials":2148,"activeCount":14},[],{"trials":2150,"activeCount":14},[],{"intervention":2152,"totalTrials":174,"cells":2153},"Omeprazole",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2171,"PHASE3":2173,"PHASE4":2175,"NA":2177},{"trials":2155,"activeCount":14},[],{"trials":2157,"activeCount":14},[2158],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2161,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":170,"conditions":2165,"interventions":2166},"NCT04246762","Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4",[87],"2022-06-08","2022-10-26","2021-11-16",[25],[2167,2152,2168,2169,2170],"Olokizumab","Caffeine","Warfarin+ Vitamin K","Midazolam",{"trials":2172,"activeCount":14},[],{"trials":2174,"activeCount":14},[],{"trials":2176,"activeCount":14},[],{"trials":2178,"activeCount":14},[],{"intervention":2168,"totalTrials":174,"cells":2180},{"EARLY_PHASE1":2181,"PHASE1":2183,"PHASE2":2189,"PHASE3":2191,"PHASE4":2193,"NA":2195},{"trials":2182,"activeCount":14},[],{"trials":2184,"activeCount":14},[2185],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2186,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":170,"conditions":2187,"interventions":2188},[87],[25],[2167,2152,2168,2169,2170],{"trials":2190,"activeCount":14},[],{"trials":2192,"activeCount":14},[],{"trials":2194,"activeCount":14},[],{"trials":2196,"activeCount":14},[],{"intervention":2169,"totalTrials":174,"cells":2198},{"EARLY_PHASE1":2199,"PHASE1":2201,"PHASE2":2207,"PHASE3":2209,"PHASE4":2211,"NA":2213},{"trials":2200,"activeCount":14},[],{"trials":2202,"activeCount":14},[2203],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2204,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":170,"conditions":2205,"interventions":2206},[87],[25],[2167,2152,2168,2169,2170],{"trials":2208,"activeCount":14},[],{"trials":2210,"activeCount":14},[],{"trials":2212,"activeCount":14},[],{"trials":2214,"activeCount":14},[],{"intervention":2170,"totalTrials":174,"cells":2216},{"EARLY_PHASE1":2217,"PHASE1":2219,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2218,"activeCount":14},[],{"trials":2220,"activeCount":14},[2221],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2222,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":170,"conditions":2223,"interventions":2224},[87],[25],[2167,2152,2168,2169,2170],{"trials":2226,"activeCount":14},[],{"trials":2228,"activeCount":14},[],{"trials":2230,"activeCount":14},[],{"trials":2232,"activeCount":14},[],{"intervention":2234,"totalTrials":174,"cells":2235},"Ixabepilone, 5 mg\u002Fd",{"EARLY_PHASE1":2236,"PHASE1":2238,"PHASE2":2255,"PHASE3":2257,"PHASE4":2259,"NA":2261},{"trials":2237,"activeCount":14},[],{"trials":2239,"activeCount":14},[2240],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2243,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2246,"interventions":2247},"NCT00422097","A Phase I Study of Oral Ixabepilone in Subjects With Advanced Cancer",[87],"2011-04",40,[30],[2234,2248,2249,2250,2251,2252,2253,2254],"Ixabepilone, 10 mg\u002Fd","Ixabepilone, 15 mg\u002Fd","Ixabepilone, 20 mg\u002Fd","Ixabepilone, 25 mg\u002Fd","Ixabepilone, 30 mg\u002Fd","Ixabepilone, 25 mg, with famotidine","Ixabepilone, 25 mg, with food",{"trials":2256,"activeCount":14},[],{"trials":2258,"activeCount":14},[],{"trials":2260,"activeCount":14},[],{"trials":2262,"activeCount":14},[],{"intervention":2248,"totalTrials":174,"cells":2264},{"EARLY_PHASE1":2265,"PHASE1":2267,"PHASE2":2273,"PHASE3":2275,"PHASE4":2277,"NA":2279},{"trials":2266,"activeCount":14},[],{"trials":2268,"activeCount":14},[2269],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2270,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2271,"interventions":2272},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2274,"activeCount":14},[],{"trials":2276,"activeCount":14},[],{"trials":2278,"activeCount":14},[],{"trials":2280,"activeCount":14},[],{"intervention":2249,"totalTrials":174,"cells":2282},{"EARLY_PHASE1":2283,"PHASE1":2285,"PHASE2":2291,"PHASE3":2293,"PHASE4":2295,"NA":2297},{"trials":2284,"activeCount":14},[],{"trials":2286,"activeCount":14},[2287],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2288,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2289,"interventions":2290},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2292,"activeCount":14},[],{"trials":2294,"activeCount":14},[],{"trials":2296,"activeCount":14},[],{"trials":2298,"activeCount":14},[],{"intervention":2250,"totalTrials":174,"cells":2300},{"EARLY_PHASE1":2301,"PHASE1":2303,"PHASE2":2309,"PHASE3":2311,"PHASE4":2313,"NA":2315},{"trials":2302,"activeCount":14},[],{"trials":2304,"activeCount":14},[2305],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2306,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2307,"interventions":2308},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2310,"activeCount":14},[],{"trials":2312,"activeCount":14},[],{"trials":2314,"activeCount":14},[],{"trials":2316,"activeCount":14},[],{"intervention":2251,"totalTrials":174,"cells":2318},{"EARLY_PHASE1":2319,"PHASE1":2321,"PHASE2":2327,"PHASE3":2329,"PHASE4":2331,"NA":2333},{"trials":2320,"activeCount":14},[],{"trials":2322,"activeCount":14},[2323],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2324,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2325,"interventions":2326},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2328,"activeCount":14},[],{"trials":2330,"activeCount":14},[],{"trials":2332,"activeCount":14},[],{"trials":2334,"activeCount":14},[],{"intervention":2252,"totalTrials":174,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2345,"PHASE3":2347,"PHASE4":2349,"NA":2351},{"trials":2338,"activeCount":14},[],{"trials":2340,"activeCount":14},[2341],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2342,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2343,"interventions":2344},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2346,"activeCount":14},[],{"trials":2348,"activeCount":14},[],{"trials":2350,"activeCount":14},[],{"trials":2352,"activeCount":14},[],{"intervention":2253,"totalTrials":174,"cells":2354},{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2363,"PHASE3":2365,"PHASE4":2367,"NA":2369},{"trials":2356,"activeCount":14},[],{"trials":2358,"activeCount":14},[2359],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2360,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2361,"interventions":2362},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2364,"activeCount":14},[],{"trials":2366,"activeCount":14},[],{"trials":2368,"activeCount":14},[],{"trials":2370,"activeCount":14},[],{"intervention":2254,"totalTrials":174,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2381,"PHASE3":2383,"PHASE4":2385,"NA":2387},{"trials":2374,"activeCount":14},[],{"trials":2376,"activeCount":14},[2377],{"nctId":2241,"briefTitle":2242,"status":103,"phases":2378,"primaryCompletion":868,"completion":2244,"start":798,"enrollment":2245,"conditions":2379,"interventions":2380},[87],[30],[2234,2248,2249,2250,2251,2252,2253,2254],{"trials":2382,"activeCount":14},[],{"trials":2384,"activeCount":14},[],{"trials":2386,"activeCount":14},[],{"trials":2388,"activeCount":14},[],{"intervention":746,"totalTrials":174,"cells":2390},{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2399,"PHASE3":2401,"PHASE4":2403,"NA":2405},{"trials":2392,"activeCount":14},[],{"trials":2394,"activeCount":14},[2395],{"nctId":738,"briefTitle":739,"status":103,"phases":2396,"primaryCompletion":741,"completion":741,"start":742,"enrollment":743,"conditions":2397,"interventions":2398},[87],[17],[252,746],{"trials":2400,"activeCount":14},[],{"trials":2402,"activeCount":14},[],{"trials":2404,"activeCount":14},[],{"trials":2406,"activeCount":14},[],{"intervention":2408,"totalTrials":174,"cells":2409},"Ixabepilone, 32 mg\u002Fm^2 + Carboplatin, 5 mg\u002Fmin\u002FmL",{"EARLY_PHASE1":2410,"PHASE1":2412,"PHASE2":2424,"PHASE3":2426,"PHASE4":2428,"NA":2430},{"trials":2411,"activeCount":14},[],{"trials":2413,"activeCount":14},[2414],{"nctId":2415,"briefTitle":2416,"status":103,"phases":2417,"primaryCompletion":2418,"completion":2418,"start":829,"enrollment":2419,"conditions":2420,"interventions":2422},"NCT00683904","Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer",[87],"2009-09",12,[2421],"Non-small Cell Lung Cancer (NSCLC)",[2408,2423],"Ixabepilone, 32 mg\u002Fm^2 + Carboplatin, 6 mg\u002Fmin\u002FmL",{"trials":2425,"activeCount":14},[],{"trials":2427,"activeCount":14},[],{"trials":2429,"activeCount":14},[],{"trials":2431,"activeCount":14},[],{"intervention":2423,"totalTrials":174,"cells":2433},{"EARLY_PHASE1":2434,"PHASE1":2436,"PHASE2":2442,"PHASE3":2444,"PHASE4":2446,"NA":2448},{"trials":2435,"activeCount":14},[],{"trials":2437,"activeCount":14},[2438],{"nctId":2415,"briefTitle":2416,"status":103,"phases":2439,"primaryCompletion":2418,"completion":2418,"start":829,"enrollment":2419,"conditions":2440,"interventions":2441},[87],[2421],[2408,2423],{"trials":2443,"activeCount":14},[],{"trials":2445,"activeCount":14},[],{"trials":2447,"activeCount":14},[],{"trials":2449,"activeCount":14},[],{"intervention":2451,"totalTrials":174,"cells":2452},"RPH-001",{"EARLY_PHASE1":2453,"PHASE1":2455,"PHASE2":2466,"PHASE3":2468,"PHASE4":2470,"NA":2472},{"trials":2454,"activeCount":14},[],{"trials":2456,"activeCount":14},[2457],{"nctId":2458,"briefTitle":2459,"status":103,"phases":2460,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":141,"conditions":2463,"interventions":2464},"NCT03659305","Pharmacokinetic Equivalence and Safety Study of RPH-001 and Avastin®",[87],"2019-01-26","2018-07-10",[27],[2451,2465],"Avastin",{"trials":2467,"activeCount":14},[],{"trials":2469,"activeCount":14},[],{"trials":2471,"activeCount":14},[],{"trials":2473,"activeCount":14},[],{"intervention":2465,"totalTrials":174,"cells":2475},{"EARLY_PHASE1":2476,"PHASE1":2478,"PHASE2":2484,"PHASE3":2486,"PHASE4":2488,"NA":2490},{"trials":2477,"activeCount":14},[],{"trials":2479,"activeCount":14},[2480],{"nctId":2458,"briefTitle":2459,"status":103,"phases":2481,"primaryCompletion":2461,"completion":2461,"start":2462,"enrollment":141,"conditions":2482,"interventions":2483},[87],[27],[2451,2465],{"trials":2485,"activeCount":14},[],{"trials":2487,"activeCount":14},[],{"trials":2489,"activeCount":14},[],{"trials":2491,"activeCount":14},[],{"intervention":774,"totalTrials":174,"cells":2493},{"EARLY_PHASE1":2494,"PHASE1":2496,"PHASE2":2502,"PHASE3":2504,"PHASE4":2506,"NA":2508},{"trials":2495,"activeCount":14},[],{"trials":2497,"activeCount":14},[2498],{"nctId":766,"briefTitle":767,"status":103,"phases":2499,"primaryCompletion":769,"completion":769,"start":770,"enrollment":771,"conditions":2500,"interventions":2501},[87],[33,721],[209,774],{"trials":2503,"activeCount":14},[],{"trials":2505,"activeCount":14},[],{"trials":2507,"activeCount":14},[],{"trials":2509,"activeCount":14},[],{"intervention":2511,"totalTrials":174,"cells":2512},"Ixabepilone, 32 mg\u002Fm^2 + Lapatinib, 1000 mg",{"EARLY_PHASE1":2513,"PHASE1":2515,"PHASE2":2529,"PHASE3":2531,"PHASE4":2533,"NA":2535},{"trials":2514,"activeCount":14},[],{"trials":2516,"activeCount":14},[2517],{"nctId":2518,"briefTitle":2519,"status":758,"phases":2520,"primaryCompletion":2521,"completion":2521,"start":829,"enrollment":2522,"conditions":2523,"interventions":2525},"NCT00634088","Phase I Study of Ixabepilone Plus Lapatinib With or Without Capecitabine in the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer",[87],"2010-06",13,[2524],"Locally Advanced or Metastatic Breast Cancer",[2511,2526,2527,2528],"Ixabepilone, 32 mg\u002Fm^2 + Lapatinib, 1250 mg","Ixabepilone, 40 mg\u002Fm^2 + Lapatinib, 1250 mg","Ixabepilone + Lapatinib + Capecitabine",{"trials":2530,"activeCount":14},[],{"trials":2532,"activeCount":14},[],{"trials":2534,"activeCount":14},[],{"trials":2536,"activeCount":14},[],{"intervention":2526,"totalTrials":174,"cells":2538},{"EARLY_PHASE1":2539,"PHASE1":2541,"PHASE2":2547,"PHASE3":2549,"PHASE4":2551,"NA":2553},{"trials":2540,"activeCount":14},[],{"trials":2542,"activeCount":14},[2543],{"nctId":2518,"briefTitle":2519,"status":758,"phases":2544,"primaryCompletion":2521,"completion":2521,"start":829,"enrollment":2522,"conditions":2545,"interventions":2546},[87],[2524],[2511,2526,2527,2528],{"trials":2548,"activeCount":14},[],{"trials":2550,"activeCount":14},[],{"trials":2552,"activeCount":14},[],{"trials":2554,"activeCount":14},[],{"intervention":2527,"totalTrials":174,"cells":2556},{"EARLY_PHASE1":2557,"PHASE1":2559,"PHASE2":2565,"PHASE3":2567,"PHASE4":2569,"NA":2571},{"trials":2558,"activeCount":14},[],{"trials":2560,"activeCount":14},[2561],{"nctId":2518,"briefTitle":2519,"status":758,"phases":2562,"primaryCompletion":2521,"completion":2521,"start":829,"enrollment":2522,"conditions":2563,"interventions":2564},[87],[2524],[2511,2526,2527,2528],{"trials":2566,"activeCount":14},[],{"trials":2568,"activeCount":14},[],{"trials":2570,"activeCount":14},[],{"trials":2572,"activeCount":14},[],{"intervention":2528,"totalTrials":174,"cells":2574},{"EARLY_PHASE1":2575,"PHASE1":2577,"PHASE2":2583,"PHASE3":2585,"PHASE4":2587,"NA":2589},{"trials":2576,"activeCount":14},[],{"trials":2578,"activeCount":14},[2579],{"nctId":2518,"briefTitle":2519,"status":758,"phases":2580,"primaryCompletion":2521,"completion":2521,"start":829,"enrollment":2522,"conditions":2581,"interventions":2582},[87],[2524],[2511,2526,2527,2528],{"trials":2584,"activeCount":14},[],{"trials":2586,"activeCount":14},[],{"trials":2588,"activeCount":14},[],{"trials":2590,"activeCount":14},[],{"intervention":1050,"totalTrials":174,"cells":2592},{"EARLY_PHASE1":2593,"PHASE1":2595,"PHASE2":2601,"PHASE3":2603,"PHASE4":2605,"NA":2607},{"trials":2594,"activeCount":14},[],{"trials":2596,"activeCount":14},[2597],{"nctId":1041,"briefTitle":1042,"status":103,"phases":2598,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":2599,"interventions":2600},[87],[27],[1034,1050,1051,1051,1034,1034],{"trials":2602,"activeCount":14},[],{"trials":2604,"activeCount":14},[],{"trials":2606,"activeCount":14},[],{"trials":2608,"activeCount":14},[],{"intervention":1051,"totalTrials":174,"cells":2610},{"EARLY_PHASE1":2611,"PHASE1":2613,"PHASE2":2619,"PHASE3":2621,"PHASE4":2623,"NA":2625},{"trials":2612,"activeCount":14},[],{"trials":2614,"activeCount":14},[2615],{"nctId":1041,"briefTitle":1042,"status":103,"phases":2616,"primaryCompletion":1044,"completion":1045,"start":1046,"enrollment":1047,"conditions":2617,"interventions":2618},[87],[27],[1034,1050,1051,1051,1034,1034],{"trials":2620,"activeCount":14},[],{"trials":2622,"activeCount":14},[],{"trials":2624,"activeCount":14},[],{"trials":2626,"activeCount":14},[],{"intervention":2167,"totalTrials":23,"cells":2628},{"EARLY_PHASE1":2629,"PHASE1":2631,"PHASE2":2637,"PHASE3":2639,"PHASE4":2672,"NA":2674},{"trials":2630,"activeCount":14},[],{"trials":2632,"activeCount":14},[2633],{"nctId":2159,"briefTitle":2160,"status":103,"phases":2634,"primaryCompletion":2162,"completion":2163,"start":2164,"enrollment":170,"conditions":2635,"interventions":2636},[87],[25],[2167,2152,2168,2169,2170],{"trials":2638,"activeCount":14},[],{"trials":2640,"activeCount":14},[2641,2651,2662],{"nctId":2642,"briefTitle":2643,"status":103,"phases":2644,"primaryCompletion":2645,"completion":2646,"start":2647,"enrollment":2648,"conditions":2649,"interventions":2650},"NCT02760433","Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease",[89],"2019-09-12","2019-10-01","2017-01-25",368,[25],[2167],{"nctId":2652,"briefTitle":2653,"status":727,"phases":2654,"primaryCompletion":2655,"completion":2656,"start":2657,"enrollment":2658,"conditions":2659,"interventions":2660},"NCT05187793","Study of Efficacy of Different Treatment Regimens of Olokizumab",[89],"2022-10-31","2023-04","2021-07-08",198,[20],[2167,2661],"Standard therapy",{"nctId":2663,"briefTitle":2664,"status":103,"phases":2665,"primaryCompletion":2666,"completion":2667,"start":2668,"enrollment":2669,"conditions":2670,"interventions":2671},"NCT02760368","Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease",[89],"2018-08","2018-10","2016-05-19",428,[25],[2167],{"trials":2673,"activeCount":14},[],{"trials":2675,"activeCount":14},[2676],{"nctId":2677,"briefTitle":2678,"status":103,"phases":2679,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":2682,"conditions":2683,"interventions":2684},"NCT05196477","Study of the Outcomes of Olokizumab Therapy in Hospitalized Patients With SARS-CoV-2 (COVID-19) Infection",[],"2022-08-29","2021-07-14",3087,[20],[2167,2661],{"intervention":2661,"totalTrials":130,"cells":2686},{"EARLY_PHASE1":2687,"PHASE1":2689,"PHASE2":2691,"PHASE3":2693,"PHASE4":2699,"NA":2701},{"trials":2688,"activeCount":14},[],{"trials":2690,"activeCount":14},[],{"trials":2692,"activeCount":14},[],{"trials":2694,"activeCount":14},[2695],{"nctId":2652,"briefTitle":2653,"status":727,"phases":2696,"primaryCompletion":2655,"completion":2656,"start":2657,"enrollment":2658,"conditions":2697,"interventions":2698},[89],[20],[2167,2661],{"trials":2700,"activeCount":14},[],{"trials":2702,"activeCount":14},[2703],{"nctId":2677,"briefTitle":2678,"status":103,"phases":2704,"primaryCompletion":2680,"completion":2680,"start":2681,"enrollment":2682,"conditions":2705,"interventions":2706},[],[20],[2167,2661],{"intervention":2708,"totalTrials":174,"cells":2709},"Refralon",{"EARLY_PHASE1":2710,"PHASE1":2712,"PHASE2":2714,"PHASE3":2716,"PHASE4":2718,"NA":2720},{"trials":2711,"activeCount":14},[],{"trials":2713,"activeCount":14},[],{"trials":2715,"activeCount":14},[],{"trials":2717,"activeCount":14},[],{"trials":2719,"activeCount":14},[],{"trials":2721,"activeCount":14},[2722],{"nctId":2723,"briefTitle":2724,"status":103,"phases":2725,"primaryCompletion":2726,"completion":2726,"start":2727,"enrollment":2728,"conditions":2729,"interventions":2733},"NCT05773170","Efficacy and Safety Evaluation of Refralon®, Concentrate for Solution for Intravenous Injection in Patients With Paroxysmal and Persistent Atrial Fibrillation and Flutter",[],"2023-06-01","2022-11-11",1147,[2730,2731,2732],"Paroxysmal Atrial Fibrillation","Persistent Atrial Fibrillation","Atrial Flutter",[2708]]